# US 2021/0171499 A1 · Glp-1r modulating compounds

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0171499 A1
- Document ID: US20210171499A1
- Status: Published application
- Kind: A1
- Application number: 17/077,729
- Filed: 2020-10-22
- Published: 2021-06-10
- Earliest claimed: 2019-10-25
- Assignees: Gilead Sciences, Inc.
- Applicants: Gilead Sciences, Inc.
- Inventors: Stephen E. Ammann; Gediminas J. Brizgys; James S. Cassidy; Elbert Chin; Chienhung Chou; Jeromy J. Cottell; Michael Graupe; Chao-I Hung; Kavoos Kolahdouzan; Scott D. Schroeder; Nathan D. Shapiro; Daniel G. Shore; Suzanne M. Szewczyk; James G. Taylor; Rhiannon Thomas-Tran; Nathan E. Wright; Zheng-Yu Yang; Sheila M. Zipfel
- Web page: https://patentgrep.com/patent/US20210171499A1

## CPC

- C07D 401/14: containing three or more hetero rings
- A61K 31/4439: containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole (nicotine A61K31/465)
- A61K 31/506: not condensed and containing further heterocyclic rings
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- C07D 235/16: Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D 401/10: linked by a carbon chain containing aromatic rings
- C07D 403/06: linked by a carbon chain containing only aliphatic carbon atoms
- C07D 403/10: linked by a carbon chain containing aromatic rings
- C07D 405/14: containing three or more hetero rings
- C07D 409/14: containing three or more hetero rings
- C07D 413/14: containing three or more hetero rings
- C07D 417/10: linked by a carbon chain containing aromatic rings
- C07D 417/14: containing three or more hetero rings
- C07D 471/04: Ortho-condensed systems
- C07D 471/10: Spiro-condensed systems
- C07D 493/08: Bridged systems
- C07D 493/10: Spiro-condensed systems
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present disclosure provides GLP-1R agonists, and compositions, methods, and kits thereof. Such compounds are generally useful for treating a GLP-1R mediated disease or condition in a human.

## Claims

### Claim 1

A compound of Formula (I-A-1):
or a pharmaceutically acceptable salt thereof, wherein
R1 is C1-6 alkyl, C1-6haloalkyl, C2-6 alkenyl, C2-6alkynyl, C3-10 cycloalkyl, heterocyclyl, C6-10 aryl, heteroaryl, —S—R1b, —S(O)R1b, —S(O)(NH)R1b, —S(O)2R1b, —S(O)2N(R1b)(R1c), —S(O)(NR1b)R1c, —C(O)N(R1b)(R1c), —C(O)R1b, or —C(O)OR1c,
wherein the alkyl, haloalkyl, cycloalkyl, aryl, heteroaryl, or heterocyclyl is each optionally substituted with one to four Z1;
ring A is C6-10 aryl or heteroaryl, which is each optionally substituted with one to four Z1a;
ring B is C6-10 aryl or heteroaryl, which is each optionally substituted with one to four R4;
R2 is H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6alkynyl, C3-10 cycloalkyl, heterocyclyl, C6-10 aryl, heteroaryl, —CN, —OR2a, —S—R2a, —S(O)R2a, —S(O)(NH)R2a, —S(O)2R2a, —S(O)2N(R2a)(R2b), or —S(O)(NR2a)R2b,
wherein the alkyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl is each optionally substituted with one to four Z1;
X1, X2, and X3 are each independently —N═, —C(H)═, or —C(R8)═;
R3 is H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, halogen, C3-10 cycloalkyl, heterocyclyl, C6-10 aryl, heteroaryl, —CN, —NO2, —OR3a, —C(O)R3a, —CH2C(O)OR3a, —C(O)OR3a, —C(O)N(R3a)(R3b), —N(R3a)C(O)R3b, —N(R3a)C(O)OR3b, —N(R3a)C(O)N(R3b)2, —C(O)NHS(O)2R3a, —C(O)NR3aS(O)2R3b, —C(O)NR3aS(O)2NR3bR3c, —C(O)NR3a—S(O)(═NR3b)R3c, —S(O)2R3a, —S(O)2OR3a, —S(O)2N(R3a)(R3b), —N(R3a)S(O)2R3b, —S(O)2NHC(O)R3a, —S(O)(═NR3a)R3b, —S(O)(═NR3a)NR3b, —S(═NR3a)(═NR3b)R3c, —P(O)(OR3a)(R3b), —P(O)(OR3a)(OR3b), —B(OR3a)(OR3b), or —O—C1-6alkyl-C(O)OR3a, wherein the alkyl, haloalkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl is each optionally substituted with one to four R3d;
each R3a, R3b, and R3c is independently H, C1-6 alkyl, C1-6 haloalkyl, C2-8 alkoxyalkyl, —C1-4 alkyl-N(R9a)(R9b), —C1-4 alkyl-N(R9a)C(O)—O—C1-4 alkyl-OP(O)(OR9c)2, —C1-4 alkyl-C(O)N(R9a)(R9b), —C1-4 alkyl-O—C(O)—C1-4 alkyl, —C1-4 alkyl-O—C(O)—O—C1-4 alkyl, —C1-4 alkyl-O—C(O)—C1-4 alkyl-N(R9a)(R9b), —C1-4 alkyl-O—C(O)—C1-4 alkyl-OP(O)(OR9c)2, —C1-4 alkyl-C3-8 cycloalkyl, —C1-4 alkyl-heterocyclyl, C2-6 alkenyl, C2-6 alkynyl, C3-10 cycloalkyl, heterocyclyl, C6-10 aryl, heteroaryl, —CH2CH(N(R9a)2)C(O)OR9b, —P(O)(OR9c)2, —OP(O)(OR9c)2, —CH2P(O)(OR9c)2, —CH2OP(O)(OR9c)2, —OCH2P(O)(OR9c)2, —C(O)OCH2P(O)(OR9c)2, —P(O)(R9c)(OR9d), —OP(O)(R9c)(OR9d), —CH2P(O)(R9c)(OR9d), —OCH2P(O)(R9c)(OR9d), —C(O)OCH2P(O)(R9c)(OR9d), —P(O)(N(R9c)2)2, —OP(O)(N(R9c)2)2, —CH2P(O)(N(R9c)2)2, —OCH2P(O)(N(R9c)2)2, —C(O)OCH2P(O)(N(R9c)2)2, —P(O)(N(R9c)2)(OR9d), —OP(O)(N(R9c)2)(OR9d), —CH2P(O)(N(R9c)2)(OR9d), —OCH2P(O)(N(R9c)2)(OR9d), —C(O)OCH2P(O)(N(R9c)2)(OR9d), —P(O)(R9c)(N(R9d)2), —OP(O)(R9c)(N(R9d)2), —CH2P(O)(R9c)(N(R9d)2), —OCH2P(O)(R9c)(N(R9d)2), —C(O)OCH2P(O)(R9c)(N(R9d)2), or C1-6 alkyl-heterocyclyl;
wherein the alkyl, alkenyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl is each optionally substituted with one to four Z1b,
each R4 is independently C1-9 alkyl, C1-8 haloalkyl, C1-6 haloalkoxy, C2-6 alkoxyalkyl, C2-6 alkenyl, C2-6 alkynyl, halogen, C3-15 cycloalkyl, heterocyclyl, C6-10 aryl, heteroaryl, oxo, —NO2, —CN, —N3, —O—R4a, —C(O)R4a, —C(O)O—R4a, —C(O)N(R4a)(R4b), —N(R4a)(R4b), —N(R4a)2(R4b)+, —N(R4a)—C(O)R4b, —N(R4a)C(O)O(R4b), —N(R4a)C(O)N(R4b)(R4c), —N(R4a)S(O)2(R4b), —N(R4a)S(O)2—N(R4b)(R4c), —N(R4a)S(O)2O(R4b), —OC(O)R4a, —OC(O)OR4a, —OC(O)—N(R4a)(R4b), —S—R4a, —S(O)R4a, —S(O)(NH)R4a, —S(O)2R4a, —S(O)2N(R4a)(R4b), —S(O)(NR4a)R4b, or —Si(R4a)3;
wherein the alkyl, haloalkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl is each optionally substituted with one to four Z1b;
or two R4 groups attached to adjacent ring atoms are combined with the atoms to which they are attached to form a C5-10 cycloalkyl or heterocyclyl, which is each optionally substituted with one to four Z1b;
R5a and R5b are each independently H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkoxyalkyl, halogen, C3-10 cycloalkyl, heterocyclyl, —C1-6 alkyl-N(R9a)(R9b), —CN, —OR5a1, or —N(R5a1)(R5a2);
or R5a and R5b are combined with the atoms to which they are attached to form a C3-10 cycloalkyl or heterocyclyl, which is each optionally substituted with one to four R5a3;
each R5a1 and R5a2 is independently H, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-10 cycloalkyl, heterocyclyl, C6-10 aryl, or heteroaryl, wherein the cycloalkyl, heterocyclyl, aryl, or heteroaryl is each optionally substituted with one to four R5a4;
V is —C(O)—, —O—, —N(R6a)—, or —C(R6b)(R6c)—;
R6a is H, C1-6 alkyl, C3-10 cycloalkyl, heterocyclyl, —S(O)2R6a1, or —S(O)2N(R6a1)(NR6a2), wherein the cycloalkyl or heterocyclyl is each optionally substituted with C1-6 alkyl, F, or —CN;
each R6b and R6c is independently H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkoxyalkyl, halogen, C3-10 cycloalkyl, heterocyclyl, —C1-6 alkyl-N(R9a)(R9b), —CN, —OR6c1, or —N(R6c2)(R6c3), wherein the alkyl, cycloalkyl, or heterocyclyl is each optionally substituted with one to four R6b1;
or R6b and R6c are combined with the atom to which they are attached to form C3-10 cycloalkyl or heterocyclyl, which is each optionally substituted with one to four R6b1;
or R6a or R6c is combined with one R4 group and the atoms to which they are attached to form a C5-10 cycloalkyl or heterocyclyl, which is each optionally substituted with one to four R10;
Y is —N(R7)—, —O—, —S—, —S(O)—, —S(O)2—, —S(O)(═NH)—, or —S(O)(═NR7)—;
each R1a, R3d, R5a3, R5a4, R6b1, and R10 is independently C1-6 alkyl, C1-6 haloalkyl, C1-6 alkoxy, C1-6 haloalkoxy, C2-6 alkoxyalkyl, C2-6 alkenyl, C2-6 alkynyl, halogen, C3-10 cycloalkyl, heterocyclyl, C6-10 aryl, heteroaryl, oxo, —OH, —CN, CO2R3e, —NO2, or —C(O)N(R2a)(R2b), wherein the heterocyclyl or heteroaryl is optionally substituted with C1-6 alkyl, C1-6 haloalkyl, or C1-6 haloalkoxy; and
each R6a1, R6a2, R6c1, R6c2, R6c3 and R7 is independently H, C1-6 alkyl or C3-10 cycloalkyl;
each R8 is independently C1-9 alkyl, C1-8 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, halogen, C3-15 cycloalkyl, heterocyclyl, C6-10 aryl, heteroaryl, oxo, —OH, —CN, CO2R3e, —NO2, —NH2, —N3, —SH, —O(C1-9 alkyl), —O(C1-8 haloalkyl), —O(C2-6 alkenyl), —O(C2-6 alkynyl), —O(C3-15 cycloalkyl), —O(heterocyclyl), —O(C6-10 aryl), —O(heteroaryl), —NH(C1-9 alkyl), haloalkyl), —NH(C2-6 alkenyl), —NH(C2-6 alkynyl), —NH(C3-15 cycloalkyl), —NH(heterocyclyl), —NH(C6-10 aryl), —NH(heteroaryl), —N(C1-9 alkyl)2, —N(C1-8 haloalkyl)2, —N(C2-6 alkenyl)2, —N(C2-6 alkynyl)2, —N(C3-15 cycloalkyl)2, —N(heterocyclyl)2, —N(C6-10 aryl)2, —N(heteroaryl)2, —N(C1-9 alkyl)(C1-8 haloalkyl), —N(C1-9 alkyl)(C2-6 alkenyl), —N(C1-9 alkyl)(C2-6 alkynyl), —N(C1-9 alkyl)(C3-15 cycloalkyl), —N(C1-9 alkyl)(heterocyclyl), —N(C1-9 alkyl)(C6-10 aryl), —N(C1-9 alkyl)(heteroaryl), —C(O)(C1-9 alkyl), —C(O)(C1-8 haloalkyl), —C(O)(C2-6 alkenyl), —C(O)(C2-6 alkynyl), —C(O)(C3-15 cycloalkyl), —C(O)(heterocyclyl), —C(O)(C6-10 aryl), —C(O)(heteroaryl), —C(O)O(C1-9 alkyl), —C(O)O(C1-8 haloalkyl), —C(O)O(C2-6 alkenyl), —C(O)O(C2-6 alkynyl), —C(O)O(C3-15 cycloalkyl), —C(O)O(heterocyclyl), —C(O)O(C6-10 aryl), —C(O)O(heteroaryl), —C(O)NH2, —C(O)NH(C1-9 alkyl), —C(O)NH(C1-8 haloalkyl), —C(O)NH(C2-6 alkenyl), —C(O)NH(C2-6 alkynyl), —C(O)NH(C3-15 cycloalkyl), —C(O)NH(heterocyclyl), —C(O)NH(C6-10 aryl), —C(O)NH(heteroaryl), —C(O)N(C1-9 alkyl)2, —C(O)N(C1-8 haloalkyl)2, —C(O)N(C2-6 alkenyl)2, —C(O)N(C2-6 alkynyl)2, —C(O)N(C3-15 cycloalkyl)2, —C(O)N(heterocyclyl)2, —C(O)N(C6-10 aryl)2, —C(O)N(heteroaryl)2, —NHC(O)(C1-9 alkyl), —NHC(O)(C1-8 haloalkyl), —NHC(O)(C2-6 alkenyl), —NHC(O)(C2-6 alkynyl), —NHC(O)(C3-15 cycloalkyl), —NHC(O)(heterocyclyl), —NHC(O)(C6-10 aryl), —NHC(O)(heteroaryl), —NHC(O)O(C1-9 alkyl), —NHC(O)O(C1-8 haloalkyl), —NHC(O)O(C2-6 alkenyl), —NHC(O)O(C2-6 alkynyl), —NHC(O)O(C3-15 cycloalkyl), —NHC(O)O(heterocyclyl), —NHC(O)O(C6-10 aryl), —NHC(O)O(heteroaryl), —NHC(O)NH(C1-9 alkyl), —NHC(O)NH(C1-8 haloalkyl), —NHC(O)NH(C2-6 alkenyl), —NHC(O)NH(C2-6 alkynyl), —NHC(O)NH(C3-15 cycloalkyl), —NHC(O)NH(heterocyclyl), —NHC(O)NH(C6-10 aryl), —NHC(O)NH(heteroaryl), —NHS(O)(C1-9 alkyl), —N(C1-9 alkyl)(S(O)(C1-9 alkyl), —S(C1-9 alkyl), —S(C1-8 haloalkyl), —S(C2-6 alkenyl), —S(C2-6 alkynyl), —S(C3-15 cycloalkyl), —S(heterocyclyl), —S(C6-10 aryl), —S(heteroaryl), —S(O)N(C1-9 alkyl)2, —S(O)(C1-9 alkyl), —S(O)(C1-8 haloalkyl), —S(O)(C2-6 alkenyl), —S(O)(C2-6 alkynyl), —S(O)(C3-15 cycloalkyl), —S(O)(heterocyclyl), —S(O)(C6-10 aryl), —S(O)(heteroaryl), —S(O)2(C1-9 alkyl), —S(O)2(C1-8 haloalkyl), —S(O)2(C2-6 alkenyl), —S(O)2(C2-6 alkynyl), —S(O)2(C3-15 cycloalkyl), —S(O)2(heterocyclyl), —S(O)2(C6-10 aryl), —S(O)2(heteroaryl), —S(O)(NH)(C1-9 alkyl), —S(O)2NH(C1-9 alkyl), or —S(O)2N(C1-9 alkyl)2;
wherein the alkyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl in each instance is optionally substituted with one to three C1-9 alkyl, C1-8 haloalkyl, halogen, —OH, —NH2, CO2H—O(C1-9 alkyl), —O(C1-8 haloalkyl), —O(C3-15 cycloalkyl), —O(heterocyclyl), —O(aryl), —O(heteroaryl), alkyl), —NH(C1-8 haloalkyl), —NH(C3-15 cycloalkyl), —NH(heterocyclyl), —NH(aryl), —NH(heteroaryl), —N(C1-9 alkyl)2, —N(C3-15 cycloalkyl)2, —NHC(O)(C1-8 haloalkyl), —NHC(O)(C3-15 cycloalkyl), —NHC(O)(heterocyclyl), —NHC(O)(aryl), —NHC(O)(heteroaryl), —NHC(O)O(C1-9 alkyl), —NHC(O)O(C1-8 haloalkyl), —NHC(O)O(C2-6 alkynyl), —NHC(O)O(C3-15 cycloalkyl), —NHC(O)O(heterocyclyl), —NHC(O)O(aryl), —NHC(O)O(heteroaryl), —NHC(O)NH(C1-9 alkyl), S(O)2(C1-9 alkyl), —S(O)2(C1-8 haloalkyl), —S(O)2(C3-15 cycloalkyl), —S(O)2(heterocyclyl), —S(O)2(aryl), —S(O)2(heteroaryl), —S(O)(NH)(C1-9 alkyl), —S(O)2NH(C1-9 alkyl), or —S(O)2N(C1-9 alkyl)2;
each R9a and R9b is independently H, C1-6 alkyl, or C1-6 haloalkyl, or R9a and R9b together form a 6-membered heterocyclyl;
each Z1 is independently C1-9 alkyl, C1-8 haloalkyl, C1-6 alkoxy, C1-6 haloalkoxy, C2-6 alkoxyalkyl, C2-6 alkenyl, C2-6 alkynyl, halogen, C3-15 cycloalkyl, heterocyclyl, C6-10 aryl, heteroaryl, oxo, —NO2, —N3, —CN, —O—R12a, —C(O)—R12a, —C(O)O—R12a, —C(O)—N(R12a)(R12b), —N(R12a)(R12b), —N(R12a)2(R12b)+, —N(R12a)C(O)—R12b, —N(R12a)C(O)O—R12b, —N(R12a)C(O)N(R12b)(R12c), —N(R12a)S(O)2(R12b), —NR12aS(O)2N(R12b)(R12c), —NR12aS(O)2O(R12b), —OC(O)R12a, —OC(O)OR12a, —OC(O)—N(R12a)(R12b), —S—R12a, —S(O)R12a, —S(O)(NH)R12a, —S(O)2R12a, —S(O)2N(R12a)(R12b), —S(O)(NR12a)R12b, or —Si(R12a)3;
wherein the alkyl, haloalkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl is each optionally substituted with one to four Z1a;
each Z1a is independently C1-9 alkyl, C1-8 haloalkyl, C1-6 alkoxy, C1-6 haloalkoxy, C2-6 alkoxyalkyl, C2-6 alkenyl, C2-6 alkynyl, halogen, C3-15 cycloalkyl, heterocyclyl, C6-10 aryl, heteroaryl, oxo, —NO2, —CN, —N3, —O—R12a, —C(O)R12a, —C(O)O—R12a, —C(O)N(R12a)(R12b), —N(R12a)(R12b), —N(R12a)2(R12b)+, —N(R12a)—C(O)R12b, —N(R12a)C(O)O(R12b), —N(R12a)C(O)N(R12b)(R12c), —N(R12a)S(O)2(R12b), —N(R12a)S(O)2—N(R12b)(R12c), —N(R12a)S(O)2O(R12b), —OC(O)R12a, —OC(O)OR12a, —OC(O)—N(R12a)(R12b), —S—R12a, —S(O)R12a, —S(O)(NH)R12a, —S(O)2R12a, —S(O)2N(R12a)(R12b), —S(O)(NR12a)R12b, or —Si(R12a)3;
wherein the alkyl, haloalkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl is each optionally substituted with one to four Z1b;
each Z1b is independently C1-9 alkyl, C1-8 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, halogen, C3-15 cycloalkyl, heterocyclyl, C6-10 aryl, heteroaryl, oxo, —OH, —CN, CO2R3e, —NO2, —NH2, —N3, —SH, —O(C1-9 alkyl), —O(C1-8 haloalkyl), —O(C2-6 alkenyl), —O(C2-6 alkynyl), —O(C3-15 cycloalkyl), —O(heterocyclyl), —O(C6-10 aryl), —O(heteroaryl), —NH(C1-9 alkyl), —NH(C1-8 haloalkyl), —NH(C2-6 alkenyl), —NH(C2-6 alkynyl), —NH(C3-15 cycloalkyl), —NH(heterocyclyl), —NH(C6-10 aryl), —NH(heteroaryl), —N(C1-9 alkyl)2, —N(C1-8 haloalkyl)2, —N(C2-6 alkenyl)2, —N(C2-6 alkynyl)2, —N(C3-15 cycloalkyl)2, —N(heterocyclyl)2, —N(C6-10 aryl)2, —N(heteroaryl)2, —N(C1-9 alkyl)(C1-8 haloalkyl), —N(C1-9 alkyl)(C2-6 alkenyl), —N(C1-9 alkyl)(C2-6 alkynyl), —N(C1-9 alkyl)(C3-15 cycloalkyl), —N(C1-9 alkyl)(heterocyclyl), —N(C1-9 alkyl)(C6-10 aryl), —N(C1-9 alkyl)(heteroaryl), —C(O)(C1-9 alkyl), —C(O)(C1-8 haloalkyl), —C(O)(C2-6 alkenyl), —C(O)(C2-6 alkynyl), —C(O)(C3-15 cycloalkyl), —C(O)(heterocyclyl), —C(O)(C6-10 aryl), —C(O)(heteroaryl), —C(O)O(C1-9 alkyl), —C(O)O(C1-8 haloalkyl), —C(O)O(C2-6 alkenyl), —C(O)O(C2-6 alkynyl), —C(O)O(C3-15 cycloalkyl), —C(O)O(heterocyclyl), —C(O)O(C6-10 aryl), —C(O)O(heteroaryl), —C(O)NH2, —C(O)NH(C1-9 alkyl), —C(O)NH(C1-8 haloalkyl), —C(O)NH(C2-6 alkenyl), —C(O)NH(C2-6 alkynyl), —C(O)NH(C3-15 cycloalkyl), —C(O)NH(heterocyclyl), —C(O)NH(C6-10 aryl), —C(O)NH(heteroaryl), —C(O)N(C1-9 alkyl)2, —C(O)N(C1-8 haloalkyl)2, —C(O)N(C2-6 alkenyl)2, —C(O)N(C2-6 alkynyl)2, —C(O)N(C3-15 cycloalkyl)2, —C(O)N(heterocyclyl)2, —C(O)N(C6-10 aryl)2, —C(O)N(heteroaryl)2, —NHC(O)(C1-9 alkyl), —NHC(O)(C1-8 haloalkyl), —NHC(O)(C2-6 alkenyl), —NHC(O)(C2-6 alkynyl), —NHC(O)(C3-15 cycloalkyl), —NHC(O)(heterocyclyl), —NHC(O)(C6-10 aryl), —NHC(O)(heteroaryl), —NHC(O)O(C1-9 alkyl), —NHC(O)O(C1-8 haloalkyl), —NHC(O)O(C2-6 alkenyl), —NHC(O)O(C2-6 alkynyl), —NHC(O)O(C3-15 cycloalkyl), —NHC(O)O(heterocyclyl), —NHC(O)O(C6-10 aryl), —NHC(O)O(heteroaryl), —NHC(O)NH(C1-9 alkyl), —NHC(O)NH(C1-8 haloalkyl), —NHC(O)NH(C2-6 alkenyl), —NHC(O)NH(C2-6 alkynyl), —NHC(O)NH(C3-15 cycloalkyl), —NHC(O)NH(heterocyclyl), —NHC(O)NH(C6-10 aryl), —NHC(O)NH(heteroaryl), —NHS(O)(C1-9 alkyl), —N(C1-9 alkyl)(S(O)(C1-9 alkyl), —S(C1-9 alkyl), —S(C1-8 haloalkyl), —S(C2-6 alkenyl), —S(C2-6 alkynyl), —S(C3-15 cycloalkyl), —S(heterocyclyl), —S(C6-10 aryl), —S(heteroaryl), —S(O)N(C1-9 alkyl)2, —S(O)(C1-9 alkyl), —S(O)(C1-8 haloalkyl), —S(O)(C2-6 alkenyl), —S(O)(C2-6 alkynyl), —S(O)(C3-15 cycloalkyl), —S(O)(heterocyclyl), —S(O)(C6-10 aryl), —S(O)(heteroaryl), —S(O)2(C1-9 alkyl), —S(O)2(C1-8 haloalkyl), —S(O)2(C2-6 alkenyl), —S(O)2(C2-6 alkynyl), —S(O)2(C3-15 cycloalkyl), —S(O)2(heterocyclyl), —S(O)2(C6-10 aryl), —S(O)2(heteroaryl), —S(O)(NH)(C1-9 alkyl), —S(O)2NH(C1-9 alkyl), or —S(O)2N(C1-9 alkyl)2;
wherein the alkyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl in each instance is optionally substituted with one to three C1-9 alkyl, C1-8 haloalkyl, halogen, —OH, —NH2, CO2H, —O(C1-9 alkyl), —O(C1-8 haloalkyl), —O(C3-15 cycloalkyl), —O(heterocyclyl), —O(aryl), —O(heteroaryl), —NH(C1-9 alkyl), —NH(C1-8 haloalkyl), —NH(C3-15 cycloalkyl), —NH(heterocyclyl), —NH(aryl), —NH(heteroaryl), —N(C1-9 alkyl)2, —N(C3-15 cycloalkyl)2, —NHC(O)(C1-8 haloalkyl), —NHC(O)(C3-15 cycloalkyl), —NHC(O)(heterocyclyl), —NHC(O)(aryl), —NHC(O)(heteroaryl), —NHC(O)O(C1-9 alkyl), —NHC(O)O(C1-8 haloalkyl), —NHC(O)O(C2-6 alkynyl), —NHC(O)O(C3-15 cycloalkyl), —NHC(O)O(heterocyclyl), —NHC(O)O(aryl), —NHC(O)O(heteroaryl), —NHC(O)NH(C1-9 alkyl), S(O)2(C1-9 alkyl), —S(O)2(C1-8 haloalkyl), —S(O)2(C3-15 cycloalkyl), —S(O)2(heterocyclyl), —S(O)2(aryl), —S(O)2(heteroaryl), —S(O)(NH)(C1-9 alkyl), —S(O)2NH(C1-9 alkyl), or —S(O)2N(C1-9 alkyl)2;
each R1b, R1c, R2a, R2b, R4a, R4b, R4c, R9c, R9d, R12a, R12b, and R12c is independently H, C1-9 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-15 cycloalkyl, heterocyclyl, C6-10 aryl, or heteroaryl wherein the alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl is each optionally substituted with one to four Z1b; and
each R3e is independently H, C1-6 alkyl, C1-6 haloalkyl, —C1-4 alkyl-N(R9a)(R9b), —C1-4 alkyl-C(O)N(R9a)(R9b), —C1-4 alkyl-O—C(O)—C1-4 alkyl, —C1-4 alkyl-O—C(O)—O—C1-4alkyl, —C1-4 alkyl-O—C(O)—C1-4 alkyl-N(R9a)(R9b), —C1-4 alkyl-C3-8 cycloalkyl, —C1-4 alkyl-heterocyclyl, C3-10 cycloalkyl, heterocyclyl, C6-10 aryl, heteroaryl, —P(O)(OR9c)2, —CH2P(O)(OR9c)2, —OCH2P(O)(OR9c)2, —C(O)OCH2P(O)(OR9c)2, —P(O)(R9c)(OR9d), —OP(O)(R9c)(OR9d), —CH2P(O)(R9c)(OR9d), —C(O)OCH2P(O)(R9c)(OR9d), —P(O)(N(R9c)2)2, —CH2P(O)(N(R9c)2)2, —C(O)OCH2P(O)(N(R9c)2)2, —P(O)(N(R9c)2)(OR9d), —CH2P(O)(N(R9c)2)(OR9d), —C(O)OCH2P(O)(N(R9c)2)(OR9d), —P(O)(R9c)(N(R9d)2), —CH2P(O)(R9c)(N(R9d)2), or —C(O)OCH2P(O)(R9c)(N(R9d)2); wherein the alkyl, alkenyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl is each optionally substituted with one to four Z1b; wherein each heteroaryl has 5 to 12 ring members and has one to four heteroatoms each independently N, O, or S; and
wherein each heterocyclyl has 3 to 12 ring members and has one to four heteroatoms each independently N, O, or S.

### Claim 2 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein
R1 is heterocyclyl, C6-10 aryl, or heteroaryl, which is each optionally substituted with one to three Z1.

### Claim 3 (depends on 2)

The compound of claim 2, or a pharmaceutically acceptable salt thereof, wherein
R1 is heterocyclyl, C6-10 aryl, or 6-membered heteroaryl, which is each optionally substituted with one to three Z1,
wherein Z1 is independently C1-6 alkyl, C1-6 haloalkyl, C1-6 alkoxy, C1-6 haloalkoxy, halogen, oxo, —OH, —CN, or —NO2, C3-10 cycloalkyl, 3 to 12 membered heterocyclyl having one to three heteroatoms, or 5 to 10 membered heteroaryl having one to three heteroatoms.

### Claim 4 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein
R5a is H; and
R5b is H, C1-6 alkyl, F, Cl, —OR5a1, —CN, C3-10 cycloalkyl, or heterocyclyl.

### Claim 5 (depends on 4)

The compound of claim 4, or a pharmaceutically acceptable salt thereof, wherein
R5a and R5b are each H.

### Claim 6 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein
Y is —O—.

### Claim 7 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt thereof, having the structure of Formula (Ia):
wherein
subscript p is 1, 2, or 3.

### Claim 8 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein
ring A is C6-10 aryl or 5 to 10 membered heteroaryl, wherein the aryl or heteroaryl is optionally substituted with one to three Z1a,
wherein each Z1a is independently C1-6 alkyl, C1-6 haloalkyl, C1-6 alkoxy, C1-6 haloalkoxy, C2-6 alkoxyalkyl, C2-6 alkenyl, C2-6 alkynyl, halogen, C3-10 cycloalkyl, heterocyclyl, C6-10 aryl, heteroaryl, oxo, —OH, —CN, —NO2, —OR12a, —C(O)N(R12a)(R12b), each of which is optionally substituted with Z1b.

### Claim 9 (depends on 8)

The compound of claim 8, or a pharmaceutically acceptable salt thereof, wherein
ring A is phenyl or 5 to 6 membered heteroaryl, wherein the phenyl or heteroaryl is optionally substituted with one to three Z1a.

### Claim 10 (depends on 9)

The compound of claim 9, or a pharmaceutically acceptable salt thereof, wherein
ring A is
wherein each ring is optionally substituted with one or two Z1a.

### Claim 11 (depends on 9)

The compound of claim 9, or a pharmaceutically acceptable salt thereof, wherein
ring A is
wherein each ring is optionally substituted with one or two Z1a.

### Claim 12 (depends on 7)

The compound of claim 7, or a pharmaceutically acceptable salt thereof, having the structure of Formula (Ib):
wherein
subscript p is 1, 2, or 3; and
subscript q is 0, 1 or 2.

### Claim 13 (depends on 7)

The compound of claim 7, or a pharmaceutically acceptable salt thereof, having the structure of Formula (Ib-1):
wherein
subscript p is 1, 2, or 3; and
subscript q is 0, 1 or 2.

### Claim 14 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein
ring B is phenyl or 5 to 6 membered heteroaryl, wherein the phenyl or heteroaryl is optionally substituted with one to four R4.

### Claim 15 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein
ring B is
which are each optionally substituted with one or two R4.

### Claim 16 (depends on 15)

The compound of claim 15, or a pharmaceutically acceptable salt thereof, wherein
ring B is
which are each optionally substituted with one or two R4.

### Claim 17 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein
ring B is
which is optionally substituted with one or two R4.

### Claim 18 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein ring B is substituted with one or two halogens.

### Claim 19 (depends on 7)

The compound of claim 7, or a pharmaceutically acceptable salt thereof, having the structure of Formula (Ic):
wherein
XA and XB are each independently —CH═ or —N═;
subscript n is 0, 1, 2, or 3; and
subscript p is 1, 2, or 3.

### Claim 20 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein
X1, X2, and X3 are each independently —CH═, —C(F)═, —C(Cl)═, —C(Br)═, or —C(CN)═.

### Claim 21 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein
V is —O—, —NH—, or —CH2—.

### Claim 22 (depends on 19)

The compound of claim 19, or a pharmaceutically acceptable salt thereof, having the structure of Formula (Id):
wherein
XA and XB are each independently —CH═ or —N═;
subscript n is 0, 1, 2, or 3; and
subscript p is 1, 2, or 3.

### Claim 23 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein
each Z1 is independently C1-6 alkyl, C1-6 haloalkyl, C1-6 alkoxy, C1-6 haloalkoxy, C2-6 alkoxyalkyl, C2-6 alkenyl, C2-6 alkynyl, halogen, C3-10 cycloalkyl, heterocyclyl, C6-10 aryl, heteroaryl, heterocyclyl-C1-6 alkyl, heterocyclyl-C1-6 haloalkyl, heteroaryl-C1-6 alkyl, heteroaryl-C1-6 haloalkyl, oxo, —OH, —CN, —NO2, or —C(O)N(R12a)(R12b),
wherein the heteroaryl or heterocyclyl is each optionally substituted with one to four halogen, C1-6 haloalkyl, C3-6 cycloalkyl, 4-6 membered heterocyclyl, or —CN.

### Claim 24 (depends on 23)

The compound of claim 23, or a pharmaceutically acceptable salt thereof, wherein
each Z1 is independently C1-6 alkyl, C1-6 haloalkyl, C1-6 alkoxy, C1-6 haloalkoxy, halogen, oxo, —OH, —CN, or —NO2, C3-10 cycloalkyl, 3 to 12 membered heterocyclyl having one to three heteroatoms, or 5 to 10 membered heteroaryl having one to three heteroatoms.

### Claim 25 (depends on 24)

The compound of claim 24, or a pharmaceutically acceptable salt thereof, wherein
each Z1 is independently C1-6 haloalkyl, C1-6 haloalkoxy, halogen, —CN, or 5 to 6 membered heteroaryl having one to three heteroatoms.

### Claim 26 (depends on 24)

The compound of claim 24, or a pharmaceutically acceptable salt thereof, wherein
each Z1 is independently halogen, C1-6 haloalkyl, C1-3 alkoxy, C3-10 cycloalkyl, or —CN.

### Claim 27 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt thereof, having the structure of Formula (I-A-2):
wherein
U is —CH═ or —N═;
XB is —CH═ or —N═;
RB is C1-6 alkyl, C1-6 haloalkyl, C1-6 alkoxy, C1-6 haloalkoxy, halogen, or —CN;
X1, and X2, are each independently —N═, —C(H)═, or —C(R8)═;
X3 is —C(H)═;
each R4 is independently C1-9 alkyl, C1-8 haloalkyl, C1-6 haloalkoxy, C2-6 alkenyl, C2-6 alkynyl, halogen, C3-15 cycloalkyl, heterocyclyl, C6-10 aryl, oxo, —NO2, —N3, —O—R4a, —C(O)R4a, —C(O)O—R4a, —C(O)N(R4a)(R4b), —N(R4a)(R4b), —N(R4a)2(R4b)+, —N(R4a)C(O)O(R4b), —N(R4a)C(O)N(R4b)(R4c), —N(R4a)S(O)2—N(R4b)(R4c), —N(R4a)S(O)2O(R4b), —OC(O)R4a, —OC(O)OR4a, —OC(O)—N(R4a)(R4b), —S—R4a, —S(O)R4a, —S(O)(NH)R4a, —S(O)2R4a, —S(O)2N(R4a)(R4b), —S(O)(NR4a)R4b, or —Si(R4a)3;
wherein the alkyl, haloalkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl is each optionally substituted with one to four Z1b;
or two R4 groups attached to adjacent ring atoms are combined with the atoms to which they are attached to form a C5-10 cycloalkyl or heterocyclyl, which is each optionally substituted with one to four Z1b;
V is —C(O)—, —O—, —N(R6a)—, or —C(R6b)(R6c)—;
R6a is H, C1-6 alkyl, C3-10 cycloalkyl, heterocyclyl, —S(O)2R6a1, or —S(O)2N(R6a1)(NR6a2), wherein the cycloalkyl or heterocyclyl is each optionally substituted with C1-6 alkyl, F, or —CN;
each R6b and R6c is independently H or C1-6 alkyl;
each R1a, R3d, R5a3, R5a4, and R10 is independently C1-6 alkyl, C1-6 haloalkyl, C1-6 alkoxy, C1-6 haloalkoxy, C2-6 alkoxyalkyl, C2-6 alkenyl, C2-6 alkynyl, halogen, C3-10 cycloalkyl, heterocyclyl, C6-10 aryl, heteroaryl, oxo, —OH, —CN, CO2R3e, —NO2, or —C(O)N(R2a)(R2b), wherein the heterocyclyl or heteroaryl is optionally substituted with C1-6 alkyl, C1-6 haloalkyl, or C1-6 haloalkoxy; and
each R6a1, R6a2, R6c1, R6c2, R6c3 and R7 is independently H, C1-6 alkyl or C3-10 cycloalkyl;
each R8 is independently C1-9 alkyl, C1-8 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, halogen, C3-15 cycloalkyl, heterocyclyl, C6-10 aryl, heteroaryl, oxo, —OH, —CN, CO2R3e, —NO2, —NH2, —N3, —SH, —O(C1-9 alkyl), —O(C1-8 haloalkyl), —O(C2-6 alkenyl), —O(C2-6 alkynyl), —O(C3-15 cycloalkyl), —O(heterocyclyl), —O(C6-10 aryl), —O(heteroaryl), —NH(C1-9 alkyl), —NH(C1-8 haloalkyl), —NH(C2-6 alkenyl), —NH(C2-6 alkynyl), —NH(C3-15 cycloalkyl), —NH(heterocyclyl), —NH(C6-10 aryl), —NH(heteroaryl), —N(C1-9 alkyl)2, —N(C1-8 haloalkyl), —N(C2-6 alkenyl)2, —N(C2-6 alkynyl)2, —N(C3-15 cycloalkyl)2, —N(heterocyclyl)2, —N(C6-10 aryl)2, —N(heteroaryl)2, —N(C1-9 alkyl)(C1-8 haloalkyl), —N(C1-9 alkyl)(C2-6 alkenyl), —N(C1-9 alkyl)(C2-6 alkynyl), —N(C1-9 alkyl)(C3-15 cycloalkyl), —N(C1-9 alkyl)(heterocyclyl), —N(C1-9 alkyl)(C6-10 aryl), —N(C1-9 alkyl)(heteroaryl), —C(O)(C1-9 alkyl), —C(O)(C1-8 haloalkyl), —C(O)(C2-6 alkenyl), —C(O)(C2-6 alkynyl), —C(O)(C3-15 cycloalkyl), —C(O)(heterocyclyl), —C(O)(C6-10 aryl), —C(O)(heteroaryl), —C(O)O(C1-9 alkyl), —C(O)O(C1-8 haloalkyl), —C(O)O(C2-6 alkenyl), —C(O)O(C2-6 alkynyl), —C(O)O(C3-15 cycloalkyl), —C(O)O(heterocyclyl), —C(O)O(C6-10 aryl), —C(O)O(heteroaryl), —C(O)NH2, —C(O)NH(C1-9 alkyl), —C(O)NH(C1-8 haloalkyl), —C(O)NH(C2-6 alkenyl), —C(O)NH(C2-6 alkynyl), —C(O)NH(C3-15 cycloalkyl), —C(O)NH(heterocyclyl), —C(O)NH(C6-10 aryl), —C(O)NH(heteroaryl), —C(O)N(C1-9 alkyl)2, —C(O)N(C1-8 haloalkyl)2, —C(O)N(C2-6 alkenyl)2, —C(O)N(C2-6 alkynyl)2, —C(O)N(C3-15 cycloalkyl)2, —C(O)N(heterocyclyl)2, —C(O)N(C6-10 aryl)2, —C(O)N(heteroaryl)2, —NHC(O)(C1-9 alkyl), —NHC(O)(C1-8 haloalkyl), —NHC(O)(C2-6 alkenyl), —NHC(O)(C2-6 alkynyl), —NHC(O)(C3-15 cycloalkyl), —NHC(O)(heterocyclyl), —NHC(O)(C6-10 aryl), —NHC(O)(heteroaryl), —NHC(O)O(C1-9 alkyl), —NHC(O)O(C1-8 haloalkyl), —NHC(O)O(C2-6 alkenyl), —NHC(O)O(C2-6 alkynyl), —NHC(O)O(C3-15 cycloalkyl), —NHC(O)O(heterocyclyl), —NHC(O)O(C6-10 aryl), —NHC(O)O(heteroaryl), —NHC(O)NH(C1-9 alkyl), —NHC(O)NH(C1-8 haloalkyl), —NHC(O)NH(C2-6 alkenyl), —NHC(O)NH(C2-6 alkynyl), —NHC(O)NH(C3-15 cycloalkyl), —NHC(O)NH(heterocyclyl), —NHC(O)NH(C6-10 aryl), —NHC(O)NH(heteroaryl), —NHS(O)(C1-9 alkyl), —N(C1-9 alkyl)(S(O)(C1-9 alkyl), —S(C1-9 alkyl), —S(C1-8 haloalkyl), —S(C2-6 alkenyl), —S(C2-6 alkynyl), —S(C3-15 cycloalkyl), —S(heterocyclyl), —S(C6-10 aryl), —S(heteroaryl), —S(O)N(C1-9 alkyl)2, —S(O)(C1-9 alkyl), —S(O)(C1-8 haloalkyl), —S(O)(C2-6 alkenyl), —S(O)(C2-6 alkynyl), —S(O)(C3-15 cycloalkyl), —S(O)(heterocyclyl), —S(O)(C6-10 aryl), —S(O)(heteroaryl), —S(O)2(C1-9 alkyl), —S(O)2(C1-8 haloalkyl), —S(O)2(C2-6 alkenyl), —S(O)2(C2-6 alkynyl), —S(O)2(C3-15 cycloalkyl), —S(O)2(heterocyclyl), —S(O)2(C6-10 aryl), —S(O)2(heteroaryl), —S(O)(NH)(C1-9 alkyl), —S(O)2NH(C1-9 alkyl), or —S(O)2N(C1-9 alkyl)2;
wherein the alkyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl in each instance is optionally substituted with one to three C1-9 alkyl, C1-8 haloalkyl, halogen, —OH, —NH2, CO2H—O(C1-9 alkyl), —O(C1-8 haloalkyl), —O(C3-15 cycloalkyl), —O(heterocyclyl), —O(aryl), —O(heteroaryl), —NH(C1-9 alkyl), —NH(C1-8 haloalkyl), —NH(C3-15 cycloalkyl), —NH(heterocyclyl), —NH(aryl), —NH(heteroaryl), —N(C1-9 alkyl)2, —N(C3-15 cycloalkyl)2, —NHC(O)(C1-8 haloalkyl), —NHC(O)(C3-15 cycloalkyl), —NHC(O)(heterocyclyl), —NHC(O)(aryl), —NHC(O)(heteroaryl), —NHC(O)O(C1-9 alkyl), —NHC(O)O(C1-8 haloalkyl), —NHC(O)O(C2-6 alkynyl), —NHC(O)O(C3-15 cycloalkyl), —NHC(O)O(heterocyclyl), —NHC(O)O(aryl), —NHC(O)O(heteroaryl), —NHC(O)NH(C1-9 alkyl), S(O)2(C1-9 alkyl), —S(O)2(C1-8 haloalkyl), —S(O)2(C3-15 cycloalkyl), —S(O)2(heterocyclyl), —S(O)2(aryl), —S(O)2(heteroaryl), —S(O)(NH)(C1-9 alkyl), —S(O)2NH(C1-9 alkyl), or —S(O)2N(C1-9 alkyl)2;
each R9a and R9b is independently H, C1-6 alkyl, or C1-6 haloalkyl;
each Z1 is independently C1-9 alkyl, C1-8 haloalkyl, C1-6 alkoxy, C1-6 haloalkoxy, C2-6 alkoxyalkyl, C2-6 alkenyl, C2-6 alkynyl, halogen, C3-15 cycloalkyl, heterocyclyl, C6-10 aryl, heteroaryl, oxo, —NO2, —N3, —CN, —O—R12a, —C(O)—R12a, —C(O)O—R12a, —C(O)—N(R12a)(R12b), —N(R12a)(R12b), —N(R12a)2(R12b)+, —N(R12a)C(O)—R12b, —N(R12a)C(O)O—R12b, —N(R12a)C(O)N(R12b)(R12c), —N(R12a)S(O)2(R12b), —NR12aS(O)2N(R12b)(R12c), —NR12aS(O)2O(R12b), —OC(O)R12a, —OC(O)OR12a, —OC(O)—N(R12a)(R12b), —S—R12a, —S(O)R12a, —S(O)(NH)R12a, —S(O)2R12a, —S(O)2N(R12a)(R12b), —S(O)(NR12a)R12b, or —Si(R12a)3;
wherein the alkyl, haloalkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl is each optionally substituted with one to four Z1a;
each Z1a is independently C1-9 alkyl, C1-8 haloalkyl, C1-6 alkoxy, C1-6 haloalkoxy, C2-6 alkoxyalkyl, C2-6 alkenyl, C2-6 alkynyl, halogen, C3-15 cycloalkyl, heterocyclyl, C6-10 aryl, heteroaryl, oxo, —NO2, —CN, —N3, —O—R12a, —C(O)R12a, —C(O)O—R12a, —C(O)N(R12a)(R12b), —N(R12a)(R12b), —N(R12a)2(R12b)+, —N(R12a)—C(O)R12b, —N(R12a)C(O)O(R12b), —N(R12a)C(O)N(R12b)(R12c), —N(R12a)S(O)2(R12b), —N(R12a)S(O)2—N(R12b)(R12c), —N(R12a)S(O)2O(R12b), —OC(O)R12a, —OC(O)OR12a, —OC(O)—N(R12a)(R12b), —S—R12a, —S(O)R12a, —S(O)(NH)R12a, —S(O)2R12a, —S(O)2N(R12a)(R12b), —S(O)(NR12a)R12b, or —Si(R12a)3;
wherein the alkyl, haloalkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl is each optionally substituted with one to four Z1b;
each Z1b is independently C1-9 alkyl, C1-8 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, halogen, C3-15 cycloalkyl, heterocyclyl, C6-10 aryl, heteroaryl, oxo, —OH, —CN, CO2R3e, —NO2, —NH2, —N3, —SH, —O(C1-9 alkyl), —O(C1-8 haloalkyl), —O(C2-6 alkenyl), —O(C2-6 alkynyl), —O(C3-15 cycloalkyl), —O(heterocyclyl), —O(C6-10 aryl), —O(heteroaryl), —NH(C1-9 alkyl), —NH(C1-8 haloalkyl), —NH(C2-6 alkenyl), —NH(C2-6 alkynyl), —NH(C3-15 cycloalkyl), —NH(heterocyclyl), —NH(C6-10 aryl), —NH(heteroaryl), —N(C1-9 alkyl)2, —N(C1-8 haloalkyl)2, —N(C2-6 alkenyl)2, —N(C2-6 alkynyl)2, —N(C3-15 cycloalkyl)2, —N(heterocyclyl)2, —N(C6-10 aryl)2, —N(heteroaryl)2, —N(C1-9 alkyl)(C1-8 haloalkyl), —N(C1-9 alkyl)(C2-6 alkenyl), —N(C1-9 alkyl)(C2-6 alkynyl), —N(C1-9 alkyl)(C3-15 cycloalkyl), —N(C1-9 alkyl)(heterocyclyl), —N(C1-9 alkyl)(C6-10 aryl), —N(C1-9 alkyl)(heteroaryl), —C(O)(C1-9 alkyl), —C(O)(C1-8 haloalkyl), —C(O)(C2-6 alkenyl), —C(O)(C2-6 alkynyl), —C(O)(C3-15 cycloalkyl), —C(O)(heterocyclyl), —C(O)(C6-10 aryl), —C(O)(heteroaryl), —C(O)O(C1-9 alkyl), —C(O)O(C1-8 haloalkyl), —C(O)O(C2-6 alkenyl), —C(O)O(C2-6 alkynyl), —C(O)O(C3-15 cycloalkyl), —C(O)O(heterocyclyl), —C(O)O(C6-10 aryl), —C(O)O(heteroaryl), —C(O)NH2, —C(O)NH(C1-9 alkyl), —C(O)NH(C1-8 haloalkyl), —C(O)NH(C2-6 alkenyl), —C(O)NH(C2-6 alkynyl), —C(O)NH(C3-15 cycloalkyl), —C(O)NH(heterocyclyl), —C(O)NH(C6-m aryl), —C(O)NH(heteroaryl), —C(O)N(C1-9 alkyl)2, —C(O)N(C1-8 haloalkyl)2, —C(O)N(C2-6 alkenyl)2, —C(O)N(C2-6 alkynyl)2, —C(O)N(C3-15 cycloalkyl)2, —C(O)N(heterocyclyl)2, —C(O)N(C6-10 aryl)2, —C(O)N(heteroaryl)2, —NHC(O)(C1-9 alkyl), —NHC(O)(C1-8 haloalkyl), —NHC(O)(C2-6 alkenyl), —NHC(O)(C2-6 alkynyl), —NHC(O)(C3-15 cycloalkyl), —NHC(O)(heterocyclyl), —NHC(O)(C6-10 aryl), —NHC(O)(heteroaryl), —NHC(O)O(C1-9 alkyl), —NHC(O)O(C1-8 haloalkyl), —NHC(O)O(C2-6 alkenyl), —NHC(O)O(C2-6 alkynyl), —NHC(O)O(C3-15 cycloalkyl), —NHC(O)O(heterocyclyl), —NHC(O)O(C6-10 aryl), —NHC(O)O(heteroaryl), —NHC(O)NH(C1-9 alkyl), —NHC(O)NH(C1-8 haloalkyl), —NHC(O)NH(C2-6 alkenyl), —NHC(O)NH(C2-6 alkynyl), —NHC(O)NH(C3-15 cycloalkyl), —NHC(O)NH(heterocyclyl), —NHC(O)NH(C6-10 aryl), —NHC(O)NH(heteroaryl), —NHS(O)(C1-9 alkyl), —N(C1-9 alkyl)(S(O)(C1-9 alkyl), —S(C1-9 alkyl), —S(C1-8 haloalkyl), —S(C2-6 alkenyl), —S(C2-6 alkynyl), —S(C3-5 cycloalkyl), —S(heterocyclyl), —S(C6-10 aryl), —S(heteroaryl), —S(O)N(C1-9 alkyl)2, —S(O)(C1-9 alkyl), —S(O)(C1-8 haloalkyl), —S(O)(C2-6 alkenyl), —S(O)(C2-6 alkynyl), —S(O)(C3-15 cycloalkyl), —S(O)(heterocyclyl), —S(O)(C6-10 aryl), —S(O)(heteroaryl), —S(O)2(C1-9 alkyl), —S(O)2(C1-8 haloalkyl), —S(O)2(C2-6 alkenyl), —S(O)2(C2-6 alkynyl), —S(O)2(C3-15 cycloalkyl), —S(O)2(heterocyclyl), —S(O)2(C6-10 aryl), —S(O)2(heteroaryl), —S(O)(NH)(C1-9 alkyl), —S(O)2NH(C1-9 alkyl), or —S(O)2N(C1-9 alkyl)2;
wherein the alkyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl in each instance is optionally substituted with one to three C1-9 alkyl, C1-8 haloalkyl, halogen, —OH, —NH2, CO2H, —O(C1-9 alkyl), —O(C1-8 haloalkyl), —O(C3-15 cycloalkyl), —O(heterocyclyl), —O(aryl), —O(heteroaryl), —NH(C1-9 alkyl), —NH(C1-8 haloalkyl), —NH(C3-15 cycloalkyl), —NH(heterocyclyl), —NH(aryl), —NH(heteroaryl), —N(C1-9 alkyl)2, —N(C3-15 cycloalkyl)2, —NHC(O)(C1-8 haloalkyl), —NHC(O)(C3-15 cycloalkyl), —NHC(O)(heterocyclyl), —NHC(O)(aryl), —NHC(O)(heteroaryl), —NHC(O)O(C1-9 alkyl), —NHC(O)O(C1-8 haloalkyl), —NHC(O)O(C2-6 alkynyl), —NHC(O)O(C3-15 cycloalkyl), —NHC(O)O(heterocyclyl), —NHC(O)O(aryl), —NHC(O)O(heteroaryl), —NHC(O)NH(C1-9 alkyl), S(O)2(C1-9 alkyl), —S(O)2(C1-8 haloalkyl), —S(O)2(C3-15 cycloalkyl), —S(O)2(heterocyclyl), —S(O)2(aryl), —S(O)2(heteroaryl), —S(O)(NH)(C1-9 alkyl), —S(O)2NH(C1-9 alkyl), or —S(O)2N(C1-9 alkyl)2;
each R1b, R1c, R2a, R2b, R4a, R4b, R4c, R9c, R9d, R12a, R12b, and R12c is independently H, C1-9 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-15 cycloalkyl, heterocyclyl, C6-10 aryl, or heteroaryl wherein the alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl is each optionally substituted with one to four Z1b; and
each R3e is independently H, C1-6 alkyl, C1-6 haloalkyl, —C1-4 alkyl-N(R9a)(R9b), —C1-4 alkyl-C(O)N(R9a)(R9b), —C1-4 alkyl-O—C(O)—C1-4 alkyl, —C1-4 alkyl-O—C(O)—O—C1-4alkyl, —C1-4 alkyl-O—C(O)—C1-4 alkyl-N(R9a)(R9b), —C1-4 alkyl-C3-8 cycloalkyl, —C1-4 alkyl-heterocyclyl, C3-10 cycloalkyl, heterocyclyl, C6-10 aryl, heteroaryl, —P(O)(OR9c)2, —CH2P(O)(OR9c)2, —OCH2P(O)(OR9c)2, —C(O)OCH2P(O)(OR9c)2, —P(O)(R9c)(OR9d), —OP(O)(R9c)(OR9d), —CH2P(O)(R9c)(OR9d), —C(O)OCH2P(O)(R9c)(OR9d), —P(O)(N(R9c)2)2, —CH2P(O)(N(R9c)2)2, —C(O)OCH2P(O)(N(R9c)2)2, —P(O)(N(R9c)2)(OR9d), —CH2P(O)(N(R9c)2)(OR9d), —C(O)OCH2P(O)(N(R9c)2)(OR9d), —P(O)(R9c)(N(R9d)2), —CH2P(O)(R9c)(N(R9d)2), or —C(O)OCH2P(O)(R9c)(N(R9d)2);
wherein the alkyl, alkenyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl is each optionally substituted with one to four Z1b; wherein each heteroaryl has 5 to 12 ring members and has one to four heteroatoms each independently N, O, or S; and
wherein each heterocyclyl, unless otherwise stated, has 3 to 12 ring members and has one to four heteroatoms each independently N, O, or S; and
m is 0, 1, or 2.

### Claim 28 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein
R2 is H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkoxyalkyl, C2-6 alkenyl, C2-6 alkynyl, C3-10 cycloalkyl, heterocyclyl, C6-10 aryl, heteroaryl, C1-6 alkyl-C3-10 cycloalkyl, C1-6 alkyl-heterocyclyl, C1-6 alkyl-C6-10 aryl, C1-6 alkyl-heteroaryl, C1-6 alkyl-C3-10 cycloalkyl-C1-6 alkyl, C1-6 alkyl-heterocyclyl-C1-6 alkyl, —CN, —C(O)R2a, —C(O)OR2a, —C(O)N(R2a)(R2b), —C(O)NR2cS(O)2R2a, —S(O)2R2a, —S(O)2N(R2a)(R2b), or —S(O)2NR2cC(O)R2a, wherein the alkyl, cycloalkyl, aryl, heteroaryl, and heterocyclyl are each optionally substituted with one to four Z1b,
wherein each Z1b is independently C1-6 alkyl, C1-6 haloalkyl, C1-6 alkoxy, C1-6 haloalkoxy, C2-6 alkoxyalkyl, C2-6 alkenyl, C2-6 alkynyl, halogen, C3-10 cycloalkyl, heterocyclyl, C6-10 aryl, heteroaryl, heterocyclyl-C1-6 alkyl, heterocyclyl-C1-6 haloalkyl, heteroaryl-C1-6 alkyl, heteroaryl-C1-6 haloalkyl, oxo, —OH, —CN, —NO2, or —C(O)N(R12a)(R12b).

### Claim 29 (depends on 28)

The compound of claim 28, or a pharmaceutically acceptable salt thereof, wherein
R2 is C1-6 alkyl, C3-10 cycloalkyl, heterocyclyl, heteroaryl, C1-6 alkyl-C3-10 cycloalkyl, C1-6 alkyl-heterocyclyl, C1-6 alkyl-C3-10 cycloalkyl-C1-6 alkyl, C1-6 alkyl-heterocyclyl-C1-6 alkyl, or C1-6 alkyl-heteroaryl, each of which is optionally substituted with one to four Z1b.

### Claim 30 (depends on 29)

The compound of claim 29, or a pharmaceutically acceptable salt thereof, wherein
R2 is C1-6 alkyl, which is optionally substituted with one to four Z1b.

### Claim 31 (depends on 29)

The compound of claim 29, or a pharmaceutically acceptable salt thereof, wherein
R2 is C3-10 cycloalkyl or heterocyclyl, each of which is optionally substituted with one to four Z1b.

### Claim 32 (depends on 29)

The compound of claim 29, or a pharmaceutically acceptable salt thereof, wherein
R2 is C1-6 alkyl-heterocyclyl-C1-6 alkyl or C1-6 alkyl-heterocyclyl, each of which is optionally substituted with one to four Z1b.

### Claim 33 (depends on 29)

The compound of claim 29, or a pharmaceutically acceptable salt thereof, wherein
R2 is C1-6 alkyl-C3-10 cycloalkyl or C1-6 alkyl-C3-10 cycloalkyl-C1-6 alkyl, which is each optionally substituted with one to four Z1b.

### Claim 34 (depends on 29)

The compound of claim 29, or a pharmaceutically acceptable salt thereof, wherein R2 is

### Claim 35 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein
R3 is H, halogen, heteroaryl, —C(O)NH2, —C(O)OH, —CH2C(O)OR3a, —C(O)OR3a, —C(O)N(R3a)S(O)2(R3b), —S(O)2NHC(O)R3a, —P(O)(OR3a)(OR3b), —C(O)N(R3a)S(O)2N(R3b)(R3c), or —O—C1-6alkyl-C(O)OR3a, wherein the heteroaryl is optionally substituted with one to four R3d.

### Claim 36 (depends on 35)

The compound of claim 35, or a pharmaceutically acceptable salt thereof, wherein
R3 is 5 to 6 membered heteroaryl, optionally substituted with one to four R3d.

### Claim 37 (depends on 35)

The compound of claim 35, or a pharmaceutically acceptable salt thereof, wherein
R3 is —C(O)OR3a.

### Claim 38 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein
R3a is H, C1-4 alkyl-N(R9a)(R9b), —C1-4 alkyl-N(R9a)C(O)—O—C1-4 alkyl-OP(O)(OR9c)2, CM alkyl-C(O)N(R9a)(R9b), —C1-4 alkyl-O—C(O)—C1-4 alkyl, —C1-4 alkyl-O—C(O)—O—C1-4 alkyl, —C1-4 alkyl-O—C(O)—C1-4 alkyl-N(R9a)(R9b), —C1-4 alkyl-O—C(O)—C1-4 alkyl-OP(O)(OR9c)2, —CH2CH(N(R9a)2)C(O)OR9b, —P(O)(OR9c)2, —OP(O)(OR9c)2, —CH2P(O)(OR9c)2, —CH2OP(O)(OR9c)2, —OCH2P(O)(OR9c)2, —C(O)OCH2P(O)(OR9c)2, —P(O)(R9c)(OR9d), —OP(O)(R9c)(OR9d), —CH2P(O)(R9c)(OR9d), —OCH2P(O)(R9c)(OR9d), —C(O)OCH2P(O)(R9c)(OR9d), —P(O)(N(R9c)2)2, —OP(O)(N(R9c)2)2, —CH2P(O)(N(R9c)2)2, —OCH2P(O)(N(R9c)2)2, —C(O)OCH2P(O)(N(R9c)2)2, —P(O)(N(R9c)2)(OR9d), —OP(O)(N(R9c)2)(OR9d), —CH2P(O)(N(R9c)2)(OR9d), —OCH2P(O)(N(R9c)2)(OR9d), —C(O)OCH2P(O)(N(R9c)2)(OR9d), —P(O)(R9c)(N(R9d)2), —OP(O)(R9c)(N(R9d)2), —CH2P(O)(R9c)(N(R9d)2), —OCH2P(O)(R9c)(N(R9d)2), —C(O)OCH2P(O)(R9c)(N(R9d)2), or C1-6 alkyl-heterocyclyl, wherein the wherein the alkyl or heterocyclyl is each optionally substituted with one to four halogens.

### Claim 39 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein
R3 is H, —Br,

### Claim 40 (depends on 37)

The compound of claim 37, or a pharmaceutically acceptable salt thereof, wherein
R3 is —C(O)OH.

### Claim 41 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein
each R4 is independently C1-6 alkyl, C1-6 haloalkoxy, C2-6 alkoxyalkyl, halogen, oxo, —CN, or —OR4a.

### Claim 42 (depends on 41)

The compound of claim 41, or a pharmaceutically acceptable salt thereof, wherein
each R4 is independently C1-6 alkyl, halogen, oxo, —CN, or —OR4a.

### Claim 43 (depends on 42)

The compound of claim 42, or a pharmaceutically acceptable salt thereof, wherein
each R4 is independently C1-6 alkyl, halogen, oxo, —OH, or —CN.

### Claim 44 (depends on 43)

The compound of claim 43, or a pharmaceutically acceptable salt thereof, wherein
each R4 is independently F, oxo, or —CN.

### Claim 45 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein
R6a is H, C1-6 alkyl, C3-10 cycloalkyl, or heterocyclyl.

### Claim 46 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein
each R6b and R6c is independently H, C1-3 alkyl, F, Cl, or —CN.

### Claim 47 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein R8 is C1-9 alkyl, halogen, or —O(C1-9 alkyl).

### Claim 48 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein
subscript p is 1 or 2.

### Claim 49 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein
subscript n is 0, 1 or 2.

### Claim 50 (depends on 27)

The compound of claim 27, or a pharmaceutically acceptable salt thereof, wherein
R1 is heterocyclyl, C6-10 aryl, or 6 membered heteroaryl, which is each optionally substituted with one to three C1-6 haloalkyl, halogen, or —CN;
RB is methyl, halogen, —CN, or —OCH3;
R2 is
R3 is —C(O)R3a;
R3a is H, C1-4 alkyl-N(R9a)(R9b), —C1-4 alkyl-N(R9a)C(O)—O—C1-4 alkyl-OP(O)(OR9c)2, —C1-4 alkyl-O—C(O)—C1-4 alkyl, —C1-4 alkyl-O—C(O)—O—C1-4alkyl, —C1-4 alkyl-O—C(O)—C1-4 alkyl-N(R9a)(R9b), —C1-4 alkyl-O—C(O)—C1-4 alkyl-OP(O)(OR9c)2, —CH2CH(N(R9a)2)C(O)OR9b, —P(O)(OR9c)2, —OP(O)(OR9c)2, —CH2P(O)(OR9c)2, —CH2OP(O)(OR9c)2, or C1-6 alkyl-heterocyclyl, wherein the wherein the alkyl or heterocyclyl is each optionally substituted with one to four halogens;
each R4 is independently F, oxo, or —CN;
V is —CH2—;
R5a and R5b are each H; and
Y is —O—; and
each R8 is independently H or halogen;
each R9a, R9b, and R9c is independently H or C1-6 alkyl;
m is 0 or 1; and
n is 1 or 2.

### Claim 51 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt thereof, having the structure of any one of Examples 1 to 926.

### Claim 52

(canceled)

### Claim 53 (depends on 1)

A pharmaceutical composition comprising a pharmaceutically effective amount of a compound of claim 1, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or excipient.

### Claim 54 (depends on 53)

The pharmaceutical composition of claim 53 further comprising one or more additional therapeutic agents.

### Claim 55 (depends on 53)

The pharmaceutical composition of claim 53 for use in treating a glucagon-like peptide 1 receptor (GLP-1R) mediated disease or condition.

### Claim 56 (depends on 1)

A method of treating GLP-1R mediated disease or condition comprising administering to a subject in need thereof a pharmaceutically effective amount of a compound of claim 1, or a pharmaceutically acceptable salt thereof.

### Claim 57 (depends on 56)

The method of claim 56, wherein the disease or condition comprises a liver disease.

### Claim 58 (depends on 57)

The method of claim 57, wherein the disease or condition comprises liver fibrosis, non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), liver cirrhosis, compensated liver fibrosis, decompensated liver fibrosis, hepatocellular carcinoma, Primary Biliary Cirrhosis (PBC), or Primary Sclerosing Choleangitis (PSC).

### Claim 59 (depends on 58)

The method of claim 58, wherein the disease or condition comprises non-alcoholic fatty liver disease (NAFLD).

### Claim 60 (depends on 58)

The method of claim 58, wherein the disease or condition comprises non-alcoholic steatohepatitis (NASH).

### Claim 61 (depends on 56)

The method of claim 56, wherein the disease or condition comprises a metabolic disease.

### Claim 62 (depends on 56)

The method of claim 56, wherein the disease or condition comprises type 1 diabetes, type 2 diabetes, pre-diabetes, idiopathic type 1 diabetes, latent autoimmune diabetes, maturity onset diabetes of the young, early onset diabetes, malnutrition-related diabetes, gestational diabetes, hyperglycemia, insulin resistance, hepatic insulin resistance, impaired glucose tolerance, diabetic neuropathy, diabetic nephropathy, kidney disease, diabetic retinopathy, adipocyte dysfunction, visceral adipose deposition, obesity, eating disorders, sleep apnea, weight gain, sugar craving, dyslipidemia, hyperinsulinemia, congestive heart failure, myocardial infarction, stroke, hemorrhagic stroke, ischemic stroke, traumatic brain injury, pulmonary hypertension, restenosis after angioplasty, intermittent claudication, post-prandial lipemia, metabolic acidosis, ketosis, arthritis, left ventricular hypertrophy, Parkinson's Disease, peripheral arterial disease, macular degeneration, cataract, glomerulosclerosis, chronic renal failure, metabolic syndrome, angina pectoris, premenstrual syndrome, thrombosis, atherosclerosis, impaired glucose metabolism, vascular restenosis, dementia, or Alzheimer's disease.

### Claim 63 (depends on 56)

The method of claim 56, wherein the compound or pharmaceutically acceptable salt thereof is administered in combination with an additional therapeutic agent.

### Claim 64 (depends on 54)

The pharmaceutical composition of claim 54, wherein the additional therapeutic agent comprises an anti-obesity agent including but not limited to peptide YY or an analogue thereof, a neuropeptide Y receptor type 2 (NPYR2) agonist, a NPYR1 agonist, an NPYR5 antagonist, a cannabinoid receptor type 1 (CB1 R) antagonist, a lipase inhibitor (e.g., orlistat), a human proislet peptide (HIP), a melanocortin receptor 4 agonist (MC4R) (e.g., setmelanotide), a melanin concentrating hormone receptor 1 antagonist, a famesoid X receptor (FXR) agonist (e.g. obeticholic acid), apoptotic signal-regulating kinase (ASK-1) inhibitor, zonisamide, phentermine (alone or in combination with topiramate), a norepinephrine/dopamine reuptake inhibitor (e.g., buproprion), an opioid receptor antagonist (e.g., naltrexone), a combination of norepinephrine/dopamine reuptake inhibitor and opioid receptor antagonist (e.g., a combination of bupropion and naltrexone), a GDF-15 analog, sibutramine, a cholecystokinin agonist, amylin and analogues thereof (e.g., pramlintide), leptin and analogues thereof (e.g., metroleptin), a serotonergic agent (e.g., lorcaserin), a methionine aminopeptidase 2 (MetAP2) inhibitor (e.g., beloranib or ZGN-1061), phendimetrazine, diethylpropion, benzphetamine, an SGLT2 inhibitor (e.g., empagliflozin, canagliflozin, dapagliflozin, ipragliflozin, tofogliflozin, sergliflozin etabonate, remogliflozin etabonate, or ertugliflozin), an SGLTL1 inhibitor, a dual SGLT2/SGLT1 inhibitor, a fibroblast growth factor receptor (FGFR) modulator, an AMP-activated protein kinase (AMPK) activator, biotin, a MAS receptor modulator, or a glucagon receptor agonist (alone or in combination with another GLP-1 R agonist, e.g., liraglutide, exenatide, dulaglutide, albiglutide, lixisenatide, or semaglutide), a peroxisome proliferator-activated receptor alpha (PPARα) agonist, fish oil, an acetyl-coA carboxylase (ACC) inhibitor, a TGFβ antagonist, GFRAL agonist, and/or a pharmaceutically acceptable salt thereof.

### Claim 65

(canceled)

### Claim 66

(canceled)

### Claim 67

(canceled)
